Three Generations of β-blockers: History, Class Differences and Clinical Applicability.
暂无分享,去创建一个
[1] D. Kuster,et al. β‐adrenergic receptor signalling and its functional consequences in the diseased heart , 2016, European journal of clinical investigation.
[2] Justin Fongemie,et al. A Review of Nebivolol Pharmacology and Clinical Evidence , 2015, Drugs.
[3] J. Tanus-Santos,et al. β1-Adrenergic blockers exert antioxidant effects, reduce matrix metalloproteinase activity, and improve renovascular hypertension-induced cardiac hypertrophy. , 2014, Free radical biology & medicine.
[4] P. Negi,et al. To compare the effect of Telmisartan with Metoprolol on arterial stiffness in hypertension: prospective randomized parallel group trial. , 2014, Indian heart journal.
[5] Xin Lu,et al. Nebivolol Protects against Myocardial Infarction Injury via Stimulation of Beta 3-Adrenergic Receptors and Nitric Oxide Signaling , 2014, PloS one.
[6] R. Touyz,et al. Angiotensin II and Vascular Injury , 2014, Current Hypertension Reports.
[7] T. Berg. β1-Blockers Lower Norepinephrine Release by Inhibiting Presynaptic, Facilitating β1-Adrenoceptors in Normotensive and Hypertensive Rats , 2014, Front. Neurol..
[8] Getachew Tegegne,et al. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] Jackson T. Wright,et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.
[10] K. Ismond,et al. Potential Benefits of Therapeutic Use of β2-Adrenergic Receptor Agonists in Neuroprotection and Parkinsonμs Disease , 2014, Journal of immunology research.
[11] John Chalmers,et al. Clinical Practice Guidelines for the Management of Hypertension in the Community , 2014, Journal of clinical hypertension.
[12] J. Tanus-Santos,et al. Nebivolol attenuates prooxidant and profibrotic mechanisms involving TGF-β and MMPs, and decreases vascular remodeling in renovascular hypertension. , 2013, Free radical biology & medicine.
[13] S. Kaul,et al. Anti-inflammatory and pro-angiogenic effects of beta blockers in a canine model of chronic ischemic cardiomyopathy: comparison between carvedilol and metoprolol , 2013, Basic Research in Cardiology.
[14] W. Koch,et al. Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapy , 2013, Front. Physiol..
[15] Bin Zhang,et al. The effects of carvedilol on cardiac structural remodeling: the role of endogenous nitric oxide in the activity of carvedilol. , 2013, Molecular medicine reports.
[16] Yuan-sheng Gao,et al. Beta blockers, nitric oxide, and cardiovascular disease. , 2013, Current opinion in pharmacology.
[17] R. Rodrigo,et al. Effect of Carvedilol and Nebivolol on Oxidative Stress‐related Parameters and Endothelial Function in Patients with Essential Hypertension , 2012, Basic & clinical pharmacology & toxicology.
[18] H. Bundgaard,et al. β-Adrenergic regulation of the cardiac Na+-K+ ATPase mediated by oxidative signaling. , 2012, Trends in cardiovascular medicine.
[19] P. D. de Tombe,et al. Protein kinase A changes calcium sensitivity but not crossbridge kinetics in human cardiac myofibrils. , 2011, American journal of physiology. Heart and circulatory physiology.
[20] V. Demarco,et al. Nebivolol Improves Diastolic Dysfunction and Myocardial Remodeling Through Reductions in Oxidative Stress in the Zucker Obese Rat , 2010, Hypertension.
[21] L. Hansson,et al. THE EFFECT OF PROPRANOLOL ON PLASMA RENIN ACTIVITY AND BLOOD PRESSURE IN MILD ESSENTIAL HYPERTENSION , 2009 .
[22] R. Eggertsen,et al. Hemodynamic effects of combined beta-adrenoceptor blockade and precapillary vasodilatation in hypertension. , 2009, Acta medica Scandinavica. Supplementum.
[23] F. Charpentier,et al. Rabbit, a relevant model for the study of cardiac β3‐adrenoceptors , 2009, Experimental physiology.
[24] M. Banach,et al. Carvedilol modifies antioxidant status of patients with stable angina , 2008, Cellular & Molecular Biology Letters.
[25] A. Hänsicke,et al. Stereochemical comparison of nebivolol with other β‐blockers , 2008 .
[26] E. Saunders,et al. The Efficacy and Tolerability of Nebivolol in Hypertensive African American Patients , 2007, Journal of clinical hypertension.
[27] R. Weiss,et al. A Randomized, Double‐Blind, Placebo‐Controlled Parallel‐Group Study to Assess the Efficacy and Safety of Nebivolol, a Novel β‐Blocker, in Patients With Mild to Moderate Hypertension , 2007 .
[28] R. Schwinger,et al. NITRIC OXIDE, ERECTILE DYSFUNCTION AND BETA‐BLOCKER TREATMENT (MR NOED STUDY): BENEFIT OF NEBIVOLOL VERSUS METOPROLOL IN HYPERTENSIVE MEN , 2007, Clinical and experimental pharmacology & physiology.
[29] S. Kjeldsen,et al. The Antioxidative Effects of Long-Term Treatment Are More Pronounced for Carvedilol Than for Atenolol in Post-myocardial Infarction Patients , 2007, Journal of cardiovascular pharmacology.
[30] H. Salgado,et al. Antihypertensive agents have different ability to modulate arterial pressure and heart rate variability in 2K1C rats. , 2006, American journal of hypertension.
[31] G. Cocco,et al. The Anti-Ischemic Effect of Metoprolol in Patients with Chronic Angina Pectoris Is Gender-Specific , 2006, Cardiology.
[32] S. Douma,et al. Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. , 2006, Asian journal of andrology.
[33] Jean-Claude Tardif,et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. , 2005, European heart journal.
[34] C. Bulpitt,et al. Quality of life and antihypertensive effect with nebivolol and losartan. , 2005, American Journal of Hypertension.
[35] M. Reiter. Cardiovascular drug class specificity: β-blockers , 2004 .
[36] Graeme Eisenhofer,et al. Sources and Significance of Plasma Levels of Catechols and Their Metabolites in Humans , 2003, Journal of Pharmacology and Experimental Therapeutics.
[37] J. Balligand,et al. Modulation of cardiac contraction, relaxation and rate by the endothelial nitric oxide synthase (eNOS): lessons from genetically modified mice , 2003, The Journal of physiology.
[38] J. Hell,et al. Regulation of Cardiac L-Type Calcium Channels by Protein Kinase A and Protein Kinase C , 2000, Circulation research.
[39] M. Boskabady,et al. Bronchial responsiveness to beta‐adrenergic stimulation and enhanced beta‐blockade in asthma , 2000, Respirology.
[40] E. Lakatta,et al. Recent Advances in Cardiac b2-Adrenergic Signal Transduction , 1999 .
[41] S. Liggett,et al. Molecular and genetic basis of 2 -adrenergic receptor function , 1999 .
[42] D. Tepper. Frontiers in congestive heart failure: Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). , 1999, Congestive heart failure.
[43] Fach,et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.
[44] B. A. Evans,et al. Characterization of β‐adrenoceptor mediated smooth muscle relaxation and the detection of mRNA for β1‐, β2‐ and β3‐adrenoceptors in rat ileum , 1999 .
[45] E. Pfarr,et al. Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. , 1999, The American journal of cardiology.
[46] Y. Lacourciére,et al. Nebivolol Versus Nifedipine in the Treatment of Essential Hypertension: A Double‐Blind, Randomized, Comparative Trial , 1998, American journal of therapeutics.
[47] E. Kranias,et al. Phospholamban: a prominent regulator of myocardial contractility. , 1996, Circulation research.
[48] Y. Lacourciére,et al. A DOUBLE‐BLIND CROSSOVER COMPARISON OF NEBIVOLOL AND LISINOPRIL IN THE TREATMENT OF AMBULATORY HYPERTENSION , 1994, American journal of therapeutics.
[49] I. Macdonald,et al. Beta-adrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects. , 1990, British journal of clinical pharmacology.
[50] A. Strosberg,et al. Molecular characterization of the human beta 3-adrenergic receptor. , 1989, Science.
[51] M. Brown,et al. A comparison of the effects of adrenaline and noradrenaline on human heart: the role of beta 1- and beta 2-adrenoceptors in the stimulation of adenylate cyclase and contractile force. , 1989, European heart journal.
[52] B. Streitberg,et al. Two-Year Follow-Up of 24-Hour Indirect Blood Pressure Monitoring: An Open Study , 1988, Drugs.
[53] R. Reneman,et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. , 1988, Journal of cardiovascular pharmacology.
[54] J Ramachandran,et al. The avian beta-adrenergic receptor: primary structure and membrane topology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[55] Brian K. Kobilka,et al. Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin , 1986, Nature.
[56] R. Byington,et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. , 1986, Circulation.
[57] A. Maseri,et al. Efficacy of carvedilol (BM 14,190), a new beta-blocking drug with vasodilating properties, in exercise-induced ischemia. , 1985, The American journal of cardiology.
[58] R. Ogilvie,et al. Antihypertensive efficacy of propranolol given twice daily. , 1979, Canadian Medical Association journal.
[59] U. Smith,et al. EFFECT OF CARDIOSELECTIVE AND NON-SELECTIVE β-BLOCKADE ON THE HYPOGLYCÆMIC RESPONSE IN INSULIN-DEPENDENT DIABETICS , 1979, The Lancet.
[60] Williams Ia. Letter: Levamisole and agranulocytosis. , 1976 .
[61] T. Lohmeier,et al. Evidence for an intrarenal beta receptor in control of renin release. , 1976, The American journal of physiology.
[62] C. Chidsey,et al. Correlation of Plasma Propranolol Concentration with Therapeutic Response in Patients with Angina Pectoris , 1975, Circulation.
[63] G. P. Levy,et al. COMBINED α‐ AND β‐ADRENOCEPTOR BLOCKING DRUG AH 5158: FURTHER STUDIES ON α‐ADRENOCEPTOR BLOCKADE IN ANAESTHETIZED ANIMALS , 1975 .
[64] A. Barrett,et al. A new type of cardioselective adrenoceptive blocking drug. , 1973, British journal of pharmacology.
[65] B. Åblad,et al. Pharmacological studies of two new cardioselective adrenergic beta-receptor antagonists. , 1973, Life sciences. Pt. 1: Physiology and pharmacology.
[66] J. B. Farmer,et al. Pharmacology of AH 5158; a drug which blocks both α‐ and β‐adrenoceptors , 1972, British journal of pharmacology.
[67] J. Melnick,et al. Au-antigen particles. , 1970, The Lancet.
[68] C D Marsden,et al. Peripheral beta-adrenergic receptors concerned with tremor. , 1967, Clinical science.
[69] A. M. Lands,et al. Differentiation of Receptor Systems activated by Sympathomimetic Amines , 1967, Nature.
[70] J. Black,et al. Preliminary CommunicationsA NEW ADRENERGIC: BETA-RECEPTOR ANTAGONIST , 1964 .
[71] J. Black,et al. A NEW ADRENERGIC , 1964 .
[72] J. S. Stephenson,et al. Pharmacology of a new adrenergic beta-receptor-blocking compound (Nethalide). , 1962, Lancet.
[73] R. Ahlquist,et al. A study of the adrenotropic receptors. , 1948, The American journal of physiology.
[74] H. Dale. On some physiological actions of ergot , 1906, The Journal of physiology.
[75] A. Schutte,et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. , 2014, Journal of hypertension.
[76] A. Marks,et al. The ryanodine receptor in cardiac physiology and disease. , 2010, Advances in pharmacology.
[77] Hammond Hk,et al. Beta-adrenergic receptors and receptor signaling in heart failure. , 1999 .
[78] B. Ljung,et al. Anti-hypertensive effect of metoprolol in spontaneously hypertensive rats. , 1976, Clinical science and molecular medicine. Supplement.
[79] R G Shanks,et al. Selective blockade of adrenoceptive beta receptors in the heart. , 1968, British journal of pharmacology and chemotherapy.
[80] J. Patterson,et al. Modification by beta-adrenergic blockade of the circulatory respones to acute hypoxia in man. , 1967, The Journal of clinical investigation.